MindBio Therapeutics (MBQI.F) Stock Overview

Engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. More details

MBQI.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (A$0)

+ 1 more risk

MBQI.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

View narrative

Lou_Basenese

Community Contributor

US$7.6FV • 76.3% undervalued

5022.2%Revenue growth p.a.

598

8d ago

MindBio Therapeutics Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for MindBio Therapeutics
Historical stock prices
Current Share Price	CA$0.86
52 Week High	CA$2.44
52 Week Low	CA$0.28
Beta	-1.51
1 Month Change	43.10%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.83%

Recent updates

Shareholder Returns

	MBQI.F	US Biotechs	US Market
7D	0%	-0.2%	3.3%
1Y	n/a	40.4%	28.1%

Return vs Industry: Insufficient data to determine how MBQI.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MBQI.F performed against the US Market.

Price Volatility

Is MBQI.F's price volatile compared to industry and market?
MBQI.F volatility
MBQI.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.3%

Stable Share Price: MBQI.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MBQI.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2021	n/a	Justin Hanka	www.mindbiotherapeutics.com

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain.

MindBio Therapeutics Corp. Fundamentals Summary

How do MindBio Therapeutics's earnings and revenue compare to its market cap?
MBQI.F fundamental statistics
Market cap	US$6.05m
Earnings (TTM)	-US$4.24m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.4x

P/E Ratio

Is MBQI.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBQI.F income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$0
Gross Profit	AU$0
Other Expenses	AU$6.01m
Earnings	-AU$6.01m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.82
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-110.5%

How did MBQI.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/10 11:11
End of Day Share Price	2026/04/01 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MindBio Therapeutics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

MindBio Therapeutics Corp.OTCPK:MBQI.F Stock Report